China-headquartered innovative diagnostic company, Shuwen Biotech, has announced Dr Irina Buhimschi will support its strategic plans by acting as an advisor to the company. The seasoned researcher brings more than 25 years of experience in maternal fetal medicine, including biomarker discoveries and diagnostic applications.
Dr Buhimschi's laboratory, previously at Yale University was the first to identify misfolding of proteins and proteostasis derangements in preeclampsia similar to those in Alzheimer's disease
Dr Irina Buhimschi is the Director of the Center for Perinatal Research in the Research Institute at Nationwide Children's Hospital and Professor of Pediatrics and Obstetrics/Gynecology at The Ohio State University in Columbus Ohio. Dr. Buhimschi's work received numerous awards of excellence at national and international meetings. She has published more than 150 peer-reviewed publications and served on numerous grant review committees for the NIH, March of Dimes and private foundations. She is also the Associate Editor for Pediatric Research and a member of editorial boards for several subspecialty journals.
Dr Buhimschi's laboratory, previously at Yale University was the first to identify misfolding of proteins and proteostasis derangements in preeclampsia similar to those in Alzheimer's disease, and has developed the Congo Red test for diagnosis of preeclampsia. Shuwen Biotech has licensed the patented technologies and developed a low cost non-invasive point-of-care detection device for preeclampsia which is expected to be launched in the coming months.
"We are very happy to have Irina joining us, and are eager to draw upon her expertise in maternal fetal medicine for our further development and commercialisation of the preeclampsia detection product and other diagnostic products for perinatal conditions." said Jay Z. Zhang, Shuwen's CEO and Chairman.
